We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Companies Like Mineralys Therapeutics (NASDAQ:MLYS) Are In A Position To Invest In Growth
Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Trial
Express News | Mineralys Therapeutics Inc - Expects to Announce Topline Data in Q1 2025
Express News | Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
Mineralys Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $30 Price Target
Mineralys Therapeutics Analyst Ratings
Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Cuts Target Price to $29
Goldman Sachs analyst Richard Law CFA maintains $Mineralys Therapeutics(MLYS.US)$ with a buy rating, and adjusts the target price from $30 to $29.According to TipRanks data, the analyst has a
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $45
Stifel analyst Annabel Samimy maintains $Mineralys Therapeutics(MLYS.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 43.6%
Express News | Mineralys Therapeutics Shares Slide 18% After Posting Bigger-Than-Expected Q2 Loss
Mineralys Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results.
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $26 to $45
On Aug 14, major Wall Street analysts update their ratings for $Mineralys Therapeutics(MLYS.US)$, with price targets ranging from $26 to $45.Wells Fargo analyst Mohit Bansal maintains with a buy
Stifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Buy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat Trials
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)
Earnings Call Summary | Mineralys Therapeutics(MLYS.US) Q2 2024 Earnings Conference
Mineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call Transcript